Cargando…

The Endless Saga of Monocyte Diversity

Cancer immunotherapy relies on either restoring or activating the function of adaptive immune cells, mainly CD8(+) T lymphocytes. Despite impressive clinical success, cancer immunotherapy remains ineffective in many patients due to the establishment of tumor resistance, largely dependent on the natu...

Descripción completa

Detalles Bibliográficos
Autores principales: Canè, Stefania, Ugel, Stefano, Trovato, Rosalinda, Marigo, Ilaria, De Sanctis, Francesco, Sartoris, Silvia, Bronte, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691342/
https://www.ncbi.nlm.nih.gov/pubmed/31447834
http://dx.doi.org/10.3389/fimmu.2019.01786
_version_ 1783443354554466304
author Canè, Stefania
Ugel, Stefano
Trovato, Rosalinda
Marigo, Ilaria
De Sanctis, Francesco
Sartoris, Silvia
Bronte, Vincenzo
author_facet Canè, Stefania
Ugel, Stefano
Trovato, Rosalinda
Marigo, Ilaria
De Sanctis, Francesco
Sartoris, Silvia
Bronte, Vincenzo
author_sort Canè, Stefania
collection PubMed
description Cancer immunotherapy relies on either restoring or activating the function of adaptive immune cells, mainly CD8(+) T lymphocytes. Despite impressive clinical success, cancer immunotherapy remains ineffective in many patients due to the establishment of tumor resistance, largely dependent on the nature of tumor microenvironment. There are several cellular and molecular mechanisms at play, and the goal is to identify those that are clinically significant. Among the hematopoietic-derived cells, monocytes are endowed with high plasticity, responsible for their pro- and anti-tumoral function. Indeed, monocytes are involved in several cancer-associated processes such as immune-tolerance, metastatic spread, neoangiogenesis, and chemotherapy resistance; on the other hand, by presenting cancer-associated antigens, they can also promote and sustain anti-tumoral T cell response. Recently, by high throughput technologies, new findings have revealed previously underappreciated, profound transcriptional, epigenetic, and metabolic differences among monocyte subsets, which complement and expand our knowledge on the monocyte ontogeny, recruitment during steady state, and emergency hematopoiesis, as seen in cancer. The subdivision into discrete monocytes subsets, both in mice and humans, appears an oversimplification, whereas continuum subsets development is best for depicting the real condition. In this review, we examine the evidences sustaining the existence of a monocyte heterogeneity along with functional activities, at the primary tumor and at the metastatic niche. In particular, we describe how tumor-derived soluble factors and cell-cell contact reprogram monocyte function. Finally, we point out the role of monocytes in preparing and shaping the metastatic niche and describe relevant targetable molecules altering monocyte activities. We think that exploiting monocyte complexity can help identifying key pathways important for the treatment of cancer and several conditions where these cells are involved.
format Online
Article
Text
id pubmed-6691342
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66913422019-08-23 The Endless Saga of Monocyte Diversity Canè, Stefania Ugel, Stefano Trovato, Rosalinda Marigo, Ilaria De Sanctis, Francesco Sartoris, Silvia Bronte, Vincenzo Front Immunol Immunology Cancer immunotherapy relies on either restoring or activating the function of adaptive immune cells, mainly CD8(+) T lymphocytes. Despite impressive clinical success, cancer immunotherapy remains ineffective in many patients due to the establishment of tumor resistance, largely dependent on the nature of tumor microenvironment. There are several cellular and molecular mechanisms at play, and the goal is to identify those that are clinically significant. Among the hematopoietic-derived cells, monocytes are endowed with high plasticity, responsible for their pro- and anti-tumoral function. Indeed, monocytes are involved in several cancer-associated processes such as immune-tolerance, metastatic spread, neoangiogenesis, and chemotherapy resistance; on the other hand, by presenting cancer-associated antigens, they can also promote and sustain anti-tumoral T cell response. Recently, by high throughput technologies, new findings have revealed previously underappreciated, profound transcriptional, epigenetic, and metabolic differences among monocyte subsets, which complement and expand our knowledge on the monocyte ontogeny, recruitment during steady state, and emergency hematopoiesis, as seen in cancer. The subdivision into discrete monocytes subsets, both in mice and humans, appears an oversimplification, whereas continuum subsets development is best for depicting the real condition. In this review, we examine the evidences sustaining the existence of a monocyte heterogeneity along with functional activities, at the primary tumor and at the metastatic niche. In particular, we describe how tumor-derived soluble factors and cell-cell contact reprogram monocyte function. Finally, we point out the role of monocytes in preparing and shaping the metastatic niche and describe relevant targetable molecules altering monocyte activities. We think that exploiting monocyte complexity can help identifying key pathways important for the treatment of cancer and several conditions where these cells are involved. Frontiers Media S.A. 2019-08-06 /pmc/articles/PMC6691342/ /pubmed/31447834 http://dx.doi.org/10.3389/fimmu.2019.01786 Text en Copyright © 2019 Canè, Ugel, Trovato, Marigo, De Sanctis, Sartoris and Bronte. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Canè, Stefania
Ugel, Stefano
Trovato, Rosalinda
Marigo, Ilaria
De Sanctis, Francesco
Sartoris, Silvia
Bronte, Vincenzo
The Endless Saga of Monocyte Diversity
title The Endless Saga of Monocyte Diversity
title_full The Endless Saga of Monocyte Diversity
title_fullStr The Endless Saga of Monocyte Diversity
title_full_unstemmed The Endless Saga of Monocyte Diversity
title_short The Endless Saga of Monocyte Diversity
title_sort endless saga of monocyte diversity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691342/
https://www.ncbi.nlm.nih.gov/pubmed/31447834
http://dx.doi.org/10.3389/fimmu.2019.01786
work_keys_str_mv AT canestefania theendlesssagaofmonocytediversity
AT ugelstefano theendlesssagaofmonocytediversity
AT trovatorosalinda theendlesssagaofmonocytediversity
AT marigoilaria theendlesssagaofmonocytediversity
AT desanctisfrancesco theendlesssagaofmonocytediversity
AT sartorissilvia theendlesssagaofmonocytediversity
AT brontevincenzo theendlesssagaofmonocytediversity
AT canestefania endlesssagaofmonocytediversity
AT ugelstefano endlesssagaofmonocytediversity
AT trovatorosalinda endlesssagaofmonocytediversity
AT marigoilaria endlesssagaofmonocytediversity
AT desanctisfrancesco endlesssagaofmonocytediversity
AT sartorissilvia endlesssagaofmonocytediversity
AT brontevincenzo endlesssagaofmonocytediversity